Search hospitals > Kansas > Wichita
Ascension Via Christi Hospitals Wichita
Claim this profileWichita, Kansas 67214
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Adenocarcinoma
281 reported clinical trials
4 medical researchers
Summary
Ascension Via Christi Hospitals Wichita is a medical facility located in Wichita, Kansas. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Ascension Via Christi Hospitals Wichita is involved with conducting 281 clinical trials across 456 conditions. There are 4 research doctors associated with this hospital, such as Shaker Dakhil, M.D., Bassem Chehab, Dennis F. Moore, and Aziz Maksoud, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
HER2 positive
Top PIs
Shaker Dakhil, M.D.Cancer Center of Kansas - Wichita5 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
81 reported clinical trials
168 drugs studied
Bassem ChehabCardiovascular Research Institute of Kansas2 years of reported clinical research
Studies Mitral Valve Regurgitation
Studies Heart Failure
20 reported clinical trials
27 drugs studied
Dennis F. MooreAscension Via Christi Hospitals Wichita3 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
27 reported clinical trials
74 drugs studied
Aziz Maksoud, MDCardiovascular Research Institute of Kansas4 years of reported clinical research
Studies Coronary Artery Disease
Studies Coronary Heart Disease
5 reported clinical trials
7 drugs studied
Clinical Trials running at Ascension Via Christi Hospitals Wichita
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Bladder Carcinoma
Bladder Cancer
Cancer
Prostate Cancer
Renal Cell Carcinoma
Small Cell Lung Cancer
Multiple Myeloma
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Omitting Radiation Therapy
for Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Ascension Via Christi Hospitals Wichita?
Ascension Via Christi Hospitals Wichita is a medical facility located in Wichita, Kansas. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Ascension Via Christi Hospitals Wichita is involved with conducting 281 clinical trials across 456 conditions. There are 4 research doctors associated with this hospital, such as Shaker Dakhil, M.D., Bassem Chehab, Dennis F. Moore, and Aziz Maksoud, MD.